Scopus BioPharma Inc.

OTC: SCPS · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001772028Reports USD

#1161 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ 16GM —SS 24

v0.1 · 25/100 weight · pillars only

↑ workforce scale, listing tenure · ↓ Piotroski F, return on assets

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$11.6M

Employees

as of 2026-08-29

Market cap

$16.8k

as of 2026-08-29

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02022

Net income-$11.6M-$11.6M2022

Operating income-$11.7M-$11.7M2022

Total assets$392.3k$392.3k2022

Equity-$6.6M-$6.6M2022

Revenue trend

FY2020 – FY2022 · USD

FY20

FY21

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Scopus BioPharma Inc.’s revenue?

Scopus BioPharma Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Petlife Pharmaceuticals, Inc.——Healthcare Solutions Management Group, Inc.——Stem Cell Authority, Ltd.——ARYx Therapeutics, Inc.——VioQuest Pharmaceuticals, Inc.——Golden Developing Solutions, Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOAlan D. Horsager

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeOTC: SCPS

Employees13

IPO date2020-12-16

Latest filings

8-K2023-08-18 10-Q2023-08-11 8-K2023-08-11 DEF 14A2023-07-21 10-Q2023-05-12 10-K2023-04-14 8-K2022-12-16 8-K2022-12-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.